Literature DB >> 6447485

Dacron interposition shunts for portal hypertension. An analysis of morbidity correlates.

R B Smith, W D Warren, A A Salam, W J Millikan, J D Ansley, J T Galambos, M Kutner, R P Bain.   

Abstract

Analysis of 79 Dacron interposition shunts performed at Emory University from 1971 to 1977 identified a number of preoperative characteristics that correlate with short-term and long-term morbidity. Initial hospital mortality was related to the degree of elevation of the bilirubin and serum glutamic oxaloacetic transaminase (SGOT), to the presence of encephalopathy and to the urgency of the shunt procedure. Cumulative survival correlated best with the preoperative SGOT and bilirubin values, but other variables, including the Child's classification, preoperative encephalopathy, serum albumin, and the age of the patient at the time of operation, also exhibited significant associations. The hospital mortality of 13% and cumulative mortality of 48% in this series are in substantial agreement with similar reports in the literature. This experience differs widely from that described by most authors, however, in two other important respects: 1) significant hepatic encephalopathy has been observed in 45% of these hospital survivors, and 2) almost one-quarter of these patients have experienced spontaneous shunt closure. Thus, major shunt related complications have occurred in 70% of the patients to date. This incidence of undesirable consequences raises a serious question concerning the continued use of the Dacron interposition shunt for elective portal decompression.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6447485      PMCID: PMC1344798          DOI: 10.1097/00000658-198007000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Portal vein thrombosis: thrombectomy and porta-caval anastomosis with the use of a graft.

Authors:  K S YEOH; B EISEMAN
Journal:  Singapore Med J       Date:  1962-06       Impact factor: 1.858

3.  Portal hypertension. Use of venous grafts when side to side anastomosis is impossible.

Authors:  J T REYNOLDS; H W SOUTHWICK
Journal:  AMA Arch Surg       Date:  1951-06

4.  Prospective comparative clinical trial with distal splenorenal and mesocaval shunts.

Authors:  F A Reichle; W F Fahmy; M Golsorkhi
Journal:  Am J Surg       Date:  1979-01       Impact factor: 2.565

5.  Early and late morbidity of portasystemic shunts including experience with seven H-grafts.

Authors:  R B Smith; G D Perdue
Journal:  Am J Gastroenterol       Date:  1972-10       Impact factor: 10.864

6.  Interposition grafting with expanded polytetrafluoroethylene for portal hypertension.

Authors:  D Rosenthal; R A Deterling; T F O'Donnell; A D Callow
Journal:  Surg Gynecol Obstet       Date:  1979-03

7.  Selective and total shunts in the treatment of bleeding varices. A randomized controlled trial.

Authors:  J T Galambos; W D Warren; D Rudman; R B Smith; A A Salam
Journal:  N Engl J Med       Date:  1976-11-11       Impact factor: 91.245

8.  Tests and management affecting survival after portacaval and spenorenal shunts.

Authors:  R B Malt; R A Malt
Journal:  Surg Gynecol Obstet       Date:  1979-08

9.  Mesocaval shunts for the control of bleeding esophageal varices.

Authors:  J L Cameron; G D Zuidema; G W Smith; D P Harrington; W C Maddrey
Journal:  Surgery       Date:  1979-03       Impact factor: 3.982

10.  Alternative use of the interposition Dacron grafts in the treatment of portal hypertension. Clinical experience with 28 cases.

Authors:  L Belli; A Marni
Journal:  J Cardiovasc Surg (Torino)       Date:  1978 Sep-Oct       Impact factor: 1.888

View more
  18 in total

1.  Budd-Chiari syndrome revisited: 38 years' experience with surgical portal decompression.

Authors:  Marshall J Orloff; Jon I Isenberg; Henry O Wheeler; Pat O Daily; Barbara Girard
Journal:  J Gastrointest Surg       Date:  2011-11-08       Impact factor: 3.452

2.  Effect of a prior portasystemic shunt on subsequent liver transplantation.

Authors:  J J Brems; J R Hiatt; A S Klein; J M Millis; J O Colonna; W J Quinones-Baldrich; K P Ramming; R W Busuttil
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

3.  Mesocaval and distal splenorenal shunts: effect on hepatic function, hepatic hemodynamics, and portal systemic encephalopathy.

Authors:  R Herz; H J Halbfass; M Rössle; D Waldmann; W Gerok
Journal:  Klin Wochenschr       Date:  1985-05-02

Review 4.  Role of distal splenorenal shunt for long-term management of variceal bleeding.

Authors:  J M Henderson
Journal:  World J Surg       Date:  1994 Mar-Apr       Impact factor: 3.352

5.  Shunt surgery for treatment of portal hypertension in children.

Authors:  J Valayer; J M Hay; F Gauthier; J Broto
Journal:  World J Surg       Date:  1985-04       Impact factor: 3.352

Review 6.  The distal splenorenal shunt: an update.

Authors:  J M Henderson; W J Millikan; W D Warren
Journal:  World J Surg       Date:  1984-10       Impact factor: 3.352

7.  Surgical treatment of portal hypertension: a historical perspective.

Authors:  A J Donovan
Journal:  World J Surg       Date:  1984-10       Impact factor: 3.352

8.  A modification of the Warren shunt.

Authors:  S Raju
Journal:  World J Surg       Date:  1982-07       Impact factor: 3.352

9.  The Emory prospective randomized trial: selective versus nonselective shunt to control variceal bleeding. Ten year follow-up.

Authors:  W J Millikan; W D Warren; J M Henderson; R B Smith; A A Salam; J T Galambos; M H Kutner; J H Keen
Journal:  Ann Surg       Date:  1985-06       Impact factor: 12.969

10.  Investigation of the portal perfusion index after low diameter mesocaval interposition and distal splenorenal shunt--a prospective study.

Authors:  K J Paquet; M A Mercado; H Klingele; R Klingele
Journal:  Surg Endosc       Date:  1991       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.